The effects of the thiol group reagent 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) on D2 dopamine receptors have been examined in three brain regions (caudate nucleus, putamen and olfactory tubercle), and in the anterior and neurointermediate lobes of the pituitary gland. Whereas the receptors in brain were insensitive to DTNB, a dosedependent inhibition of [3H]spiperone binding to D2 receptors in both lobes of the pituitary gland was observed. The effects in the pituitary could be reversed by subsequent treatment with dithiothreitol and could be prevented by prior occupancy of the receptor binding site with a ligand. The effect of DTNB was to decrease the number of ligand-binding sites without altering the affinity of those remaining. The results show that modification of a thiol group of the D2 dopamine receptor in the two lobes of the pituitary gland tested here significantly affects ligand binding. There is therefore a difference between the D2 dopamine receptor populations in brain and pituitary in their sensitivity to modification by DTNB, and this may imply the existence of different receptor isoforms in the two issues.
INTRODUCTION
Many neurotransmitters and hormones act via receptors linked to guanine nucleotide regulatory proteins (G-proteins) (Lefkowitz & Caron, 1988; Strange, 1991a; Tota et al., 1991) . From gene cloning studies it is now clear that G-protein-linked receptors for small molecules such as acetylcholine, dopamine and noradrenaline form a homologous family based on common structural motifs. The basic motifcomprises seven transmembrane spanning a-helices linked by extracellular and intracellular loops. The seven a-helices are bundled together to form the ligandbinding domain, and an understanding of the structure of this domain will be critical for drug design.
Considerable information has emerged on the amino acid residues that contribute to ligand binding through the application of site-specific mutagenesis to the receptor genes (Fraser et al., 1989; Tota et al., 1991) . In particular, for the cationic amine ligands this approach has identified an aspartic acid residue in the third membrane-spanning a-helix that may form the counteranion for the cationic amine. A complementary approach is chemical modification or protein labelling with reagents specific for particular amino acid side chains.
Using chemical modification and protein labelling, evidence has been obtained for the importance of a carboxyl group in ligand binding to D1 and D2 dopamine receptors (Williamson & Strange, 1990; Hollis & Strange, 1991) and muscarinic acetylcholine receptors (Kurtenbach et al., 1990) , and this may correspond to the aspartic acid residue mentioned earlier. In addition, modification of thiol groups affects ligand binding to D1 dopamine receptors (Sidhu et al., 1986; Dewar & Reader, 1990; Hollis & Strange, 1991) , but for D2 dopamine receptors there is some disagreement. Whereas studies with the thiol reagent N-ethylmaleimide have demonstrated an effect of thiol group modification on antagonist binding to D2 dopamine receptors from both brain and pituitary gland (Kilpatrick et al., 1982; Freedman et al., 1982; Scheuhammer & Cherian, 1985; Holden-Dye et al., 1985) , when the alternative thiol reagent 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB) was used, modification of thiol groups was without effect on ligand binding to brain D2 dopamine receptors (Williamson & Strange, 1990) . In this paper we have examined the effects of DTNB on D2 dopamine receptors more carefully.
MATERIALS AND METHODS
Except where otherwise stated, all chemicals and other materials were obtained as outlined in Leonard et al. (1987) .
Preparation of mixed mitochondrial/microsomal membrane preparations Mixed mitochondrial/microsomal membrane preparations were prepared from the different bovine tissues essentially as described by Leonard et al. (1987) . Briefly, bovine brain regions and pituitary lobes were dissected and homogenized in 0.32 Msucrose solution containing 20 mM-Hepes, pH 7.4 (9 ml/g wet wt. of tissue) with 10 strokes of a Teflon/glass homogenizer at 4 'C. The homogenate was centrifuged (1500 g, 10 min) and the supernatant was kept at 4 'C while the pellet was re-homogenized in 4.5 vol. of homogenization solution. After centrifugation the supernatants were combined and re-centrifuged (126000 g, 60min). The supernatant was discarded and the pellet was resuspended (2ml/g of tissue) in ice-cold sodium phosphate buffer (20 mm, pH 7.5). Protein was determined by the method of Lowry et al. (1951) using BSA as a standard. The tissue homogenates were stored at -80 'C.
Modification with DTNB The procedure was based on that of Means & Feeney (1971) . Mixed mitochondrial/microsomal membranes (0.75 mg of protein) were incubated with DTNB [diluted from a stock of freshly prepared DTNB (10 mM)] in a total volume of 1 ml of 20 mMsodium phosphate buffer, pH 7.5, for 2 h at 22 'C. The membranes were then washed twice by centrifugation (12000 g, 10 min, 4°C) In order to reverse the effect of DTNB, 0.75 ml of membrane suspension, modified as described above, was incubated with 0.75 ml of 10 mM-dithiothreitol in phosphate buffer and the mixture was then incubated at 22°C for a given time. The membranes were collected by centrifugation and washed twice as described above before resuspension in 0.75 ml of phosphate buffer, and were assayed for [3H]spiperone binding. Control experiments were performed on membranes that had not been treated with DTNB but which had otherwise been treated identically.
Protection of the ligand-binding site was carried out by incubating membranes (0.75 mg of protein) with either haloperidol or domperidone at a given concentration in phosphate buffer for 1 h at 22 'C. Modification with DTNB was then performed as above, but including four washes with I ml of phosphate buffer supplemented with BSA (1 mg/ml).
Ligand-binding assays with I3Hlspiperone
Mixed mitochondrial/microsomal membranes (approx. 100 ,ug of protein) were incubated with [3H]spiperone (26.0 Ci/mmol, 0.01-2.5 nM; Amersham International) in a final volume of 1 ml of phosphate buffer for 60 min at 22 'C. Mianserin (0.3 4uM) was included to block the binding of [3Hlspiperone to 5HT2 5-hydroxytryptamine receptors (Withy et al., 1981) , and specific [3H]spiperone binding was defined as that binding inhibited by 3 um-( + )-butaclamol. Assays were terminated by rapid filtration over Whatman GF/B filter paper strips in a Dynatech Automash 2000 Cell Harvester, and the filters were washed with 15 ml of ice-cold buffer (137 mM-NaCl, 2.7 mM-KCl, 8.1 mM-Na2HPO4, 1.5 mM-KH2PO4, pH 7.4) before determination of radioactivity.
RESULTS
In initial experiments the effect of a single concentration of DTNB (2.5 mM) was tested on [3H]spiperone binding to a range of bovine tissues. Whereas there was no effect in the brain regions tested (caudate nucleus, putamen and olfactory tubercle), there was a significant decrease in [3H]spiperone binding to membranes from the anterior and neurointermediate lobes of the pituitary gland ( (Fig. 2) . Under identical conditions there is no effect on the brain D2 dopamine receptor.
The assays in this report were performed using the radioligand [3H]spiperone for labelling D2 dopamine receptors. The interpretation of these experiments has been complicated by the recent cloning of D2(ShOr D2(10ng), D3 and D4 dopamine receptors, each of which will bind [3H]spiperone with high affinity (Strange, 1990 (Strange, , 1991b Sokoloffet al., 1990; Van Tol et al., 1991) . D3 and D4 dopamine receptors are present in lower numbers than D2 receptors in the brain regions chosen, based on the distribution of mRNA. In the pituitary gland, the D3 receptor is absent and the distribution of the D4 receptor has not been reported. D2(short) and D2(0ong) dopamine receptors are present in all of the tissues studied here but to different extents (Gandelman et al., 1991) ; however, these two isoforms do not differ appreciably pharmacologically and have identical amino acid sequences in the putative ligand-binding regions. Therefore it will be assumed here that the assays are detecting a receptor with a D2-dopaminereceptor-like pharmacological profile but which could be either D2(short) or D2(0ong). In addition, [3H]spiperone has also been reported to label 5HT2 5-hydroxytryptamine-and spirodecanonebinding sites, but in other analyses it has been shown that spirodecanone-binding sites are not included under the conditions used here for defining specific [3H]spiperone binding (Leonard et al., 1987) . 5HT2 5-hydroxytryptamine receptors are absent in the pituitary gland (Simmonds et al., 1986) , and in the brain [3H]spiperone binding to these receptors was suppressed by the inclusion of mianserin. Therefore in the present paper the binding of [3H] spiperone is exclusively to D2 dopamine receptors.
We chose to use DTNB as the thiol reagent in these experiments for certain reasons. It is more specific than other thiol reagents; for example, N-ethylmaleimide reacts under certain conditions with free amino groups or histidine residues. Also, the reaction of DTNB is reversible upon addition of a thiol reagent, whereas that of N-ethylmaleimide is not (Means & Feeney, 1971) .
In the present experiments the specificity of DTNB is apparent. There was no effect of DTNB on [3H]spiperone binding to D2 dopamine receptors from three brain regions (caudate nucleus, putamen and olfactory tubercle), whereas under identical conditions there was 76% inhibition of [3H]SCH23390 binding to D1 dopamine receptors in caudate nucleus (Hollis & Strange, 1991 (Dewar & Reader, 1990) , 0.45 mM (Sidhu et al., 1986) (Kilpatrick et al., 1982) , in agreement with the present study. Furthermore, two studies in which D2 dopamine receptors were labelled by [3H]sulpiride reported an effect on receptors in both pig (HoldenDye et al., 1985) and rat (Freedman et al., 1982) brain. This discrepancy cannot be explained, but certainly in the present study, using the more specific thiol reagent DTNB, a clear difference between receptors from brain and pituitary gland was seen. The possibility, however, of a species variation in D2 dopamine receptors resulting in the observed discrepancy cannot be discounted.
The results of the present study suggest, therefore, that there is a difference between D2 dopamine receptors in the brain and the pituitary gland, and that a thiol group is present on the pituitary receptor whose modification by DTNB affects ligand binding. This thiol group is either absent or inaccessible to DTNB in the brain receptor. This in turn implies that the population of bovine D2 dopamine receptors assayed by [3H]spiperone binding in the pituitary gland in these experiments differs from that in brain. This could reflect the presence of different receptor isoforms in the two sites. According to the arguments presented earlier, the isoforms likely to be detected in the present experiments are D12(short) and D2(10,g), although the distributions of receptor isoforms have been determined mainly for the rat, and the present experiments employed bovine tissues in which the relative distributions of D2, D3 and D4 receptors may be different. Recent molecular biological evidence suggests that marked distribution differences in the mRNAs for the two D2 dopamine receptor isoforms [D12(shor) and DI2(long)] exist between rat and human species in some tissues (O'Malley et al., 1990; Gandelman et al., 1991) .
The D2(short) and D2(long) isoforms differ only by the presence in the longer form of a 29-amino-acid insertion in a region of the receptor not thought to be important for ligand binding. Indeed, they do not differ in amino acid sequence in the putative ligandbinding region and do not differ pharmacologically to an appreciable extent, so it is not easy to see how different distributions of D2(short) and D2(long) in pituitary and brain could explain the present results. It should be noted, however, that in the longer isoform the insertion does contain cysteine residues, and if this were important in explaining the present results it implies either that the insertion plays a role in forming the ligand-binding site or that modification of one of these cysteine residues affects ligand binding indirectly.
A final question concerns possible mechanisms that might lead to inhibition of ligand binding if the modifiable thiol group is at the ligand-binding site. One possibility is that modification occludes part of the binding site but that the thiol group itself does not directly participate in ligand binding. Alternatively, the thiol group may actually participate in ligand binding and its modification could interfere with this. There are a number of cysteine residues within the putative transmembrane spanning region of D2 dopamine receptors, so there is ample scope for these ideas. Whatever the explanation, the results reported here suggested differences in the D2dopamine receptor populations in the brain and the pituitary gland.
